THE COST-EFFECTIVENESS OF TREATING HYPERTENSION IN ELDERLY PEOPLE - AN ANALYSIS OF THE SWEDISH TRIAL IN OLD PATIENTS WITH HYPERTENSION (STOP HYPERTENSION)

被引:57
|
作者
JOHANNESSON, M
DAHLOF, B
LINDHOLM, LH
EKBOM, T
HANSSON, L
ODEN, A
SCHERSTEN, B
WESTER, PO
JONSSON, B
机构
[1] LUND UNIV, HLTH SCI CTR, DALBY, SWEDEN
[2] UNIV HOSP UMEA, DEPT MED, UMEA, SWEDEN
[3] GOTHENBURG UNIV, DEPT MATH, S-41124 GOTHENBURG, SWEDEN
[4] GOTHENBURG UNIV, OSTRA HOSP, DEPT MED, S-41124 GOTHENBURG, SWEDEN
[5] HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA
关键词
AGE; COST-EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; ELDERLY; HEALTH ECONOMICS; HYPERTENSION;
D O I
10.1111/j.1365-2796.1993.tb00749.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. The aim of this study was to estimate the cost-effectiveness of antihypertensive treatment in elderly people based on the results of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Design. The STOP Hypertension study was a ran domized trial comparing active antihypertensive treatment with a placebo. The risk of stroke, cardiovascular disease and total mortality was significantly reduced in the actively treated group compared to placebo. Setting. One hundred and sixteen primary health care centres in Sweden. Subjects. A total of 1627 hypertensive patients aged 70-84. No patient was lost to follow-up. Interventions. Antihypertensive treatment with beta blockers and diuretics for a mean follow-up of 25 months. Main outcome measure. The cost-effectiveness ratio estimated as the net cost (the treatment cost minus saved costs of reduced cardiovascular morbidity) divided by the number of life-years gained (the increase in life expectancy from treatment). Results. The cost per life-year gained was estimated as SEK5000 for men and SEK15000 for women ($1 = SEK6; L1 = SEK10). The cost per life-year gained did not exceed SEK 100000 in any of the sensitivity analyses. Conclusions. It is concluded that treatment of elderly hypertensive patients with beta blockers and/or diuretics is cost-effective according to the results of the STOP Hypertension study.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 50 条
  • [41] Effectiveness of eszopiclone in treating sleep disorders in elderly people with hypertension and the effect on patients' sleep quality
    Rao, Shengyi
    Zheng, Ye
    Jiang, Minggang
    Xu, Ziming
    Shao, Jing
    Qiu, Jianqiang
    MINERVA MEDICA, 2023, 114 (02) : 257 - 259
  • [43] Treating hypertension - Effect of treatment and cost-effectiveness in respect to later cardiovascular diseases
    Hedner, T
    SCANDINAVIAN CARDIOVASCULAR JOURNAL, 1998, 32 : 31 - 35
  • [44] A cost-effectiveness analysis of the Chronic Disease Management Program in patients with hypertension in Korea
    Kim, Woorim
    Lee, Sang Ah
    Chun, Sung-Youn
    INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 2021, 33 (02)
  • [45] COST-EFFECTIVENESS ANALYSIS OF ACEI AND ARBS II DRUGS IN PATIENTS WITH ARTERIAL HYPERTENSION
    Tolordava, G.
    Yagudina, R.
    Arinina, E.
    VALUE IN HEALTH, 2017, 20 (09) : A617 - A617
  • [46] Cost-effectiveness of treating ocular hypertension (vol 115, pg 94, 2008)
    Nasser, Qasiem J.
    OPHTHALMOLOGY, 2008, 115 (09) : 1524 - 1524
  • [47] Cost-effectiveness Of Therapeutic Drug Monitoring In Patients With Resistant Hypertension
    Chung, Oliver
    Bonaventura, Klaus
    Sohns, Christian
    Haverkamp, Wilhelm
    Haverkamp, Wilhelm
    Dorenkamp, Marc
    Vongpatanasin, Wanpen
    HYPERTENSION, 2014, 64
  • [48] Cost-Effectiveness of Angiotensin Receptor Blockers in Moroccan Patients with Hypertension
    El Azizi, Ghizlane Berrada
    Ahid, Samir
    Abir-Khalili, Saadia
    Ellouali, Fedoua
    El Majha, Amine
    D'Ouzzane, Mouna Charif
    Mouram, Sahar
    Boukili, Abdelali
    Cherti, Mohammed
    Hassar, Mohammed
    Cherrah, Yahia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 431 - 432
  • [49] Cost-effectiveness of indapamide in patients with mild-to-moderate hypertension
    Stafylas, PC
    Sarafidis, PA
    Lasaridis, AN
    Aletras, VH
    VALUE IN HEALTH, 2005, 8 (06) : A106 - A106
  • [50] Cost-effectiveness of a lifestyle intervention for hypertension: An open randomised controlled trial
    Martikainen, J. A.
    Kastarinen, M.
    Puska, P.
    Nissinen, A.
    VALUE IN HEALTH, 2006, 9 (06) : A340 - A340